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Abstract
Background: A randomized controlled study (RCT) recently showed that short-term heart rate variability (HRV)
biofeedback in addition to standard rehabilitation care for alcohol dependence can reduce craving, anxiety and
improve cardiovascular autonomic function. In this one-year follow-up study we aimed to explore whether
completion of 2-week HRV-Biofeedback training is associated with long-term abstinence. Furthermore, we sought
to identify potential predictors of post-treatment abstinence.
Methods: We conducted a survey on abstinence in patients with alcohol dependence 1 year after completion of
an RCT comparing HRV-biofeedback in addition to inpatient rehabilitation treatment alone (controls). Abstinence
rates were compared and analysed for association with demographic data as well as psychometric and autonomic
cardiac assessment before and after completion of the biofeedback training using bivariate and multivariate
regression analyses.
Results: Out of 48 patients who participated in the RCT, 27 patients (9 females, ages 42.9 ± 8.6, mean ± SD)
completed our one-year follow-up. When including in the analysis only patients who completed follow-up, the rate
of abstinence tended to be higher in patients who underwent HRV-biofeedback 1 year earlier compared to those
who received rehabilitative treatment alone (66.7% vs 50%, p = ns). This non-significant trend was also observed in
the intention-to-treat analysis where patients who did not participate in the follow-up were assumed to have
relapsed (46,7% biofeedback vs. 33.3% controls, p = ns). Neither cardiac autonomic function nor psychometric
variables were associated with abstinence 1 year after HRV-biofeedback.
Conclusion: Our follow-up study provide a first indication of possible increase in long-term abstinence after HRV-
biofeedback for alcohol dependence in addition to rehabilitation.
Trial registration: The original randomized controlled trial was registered in the German Clinical Trials Register
(DRKS00004618). This one-year follow-up survey has not been registered.
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Background
Alcohol dependence is a major global public health
problem which affects 5.1% of the global population and
causes up to 3.3 million deaths per year, the majority of
those being related to cardiovascular diseases [1]. Al-
though integrative multimodal acute and rehabilitative
treatment regimens have been widely established to re-
duce the disease burden related to alcohol dependence,
malcompliance and low rates of adherence to treatment
are frequently compromising success of these therapies
[2, 3]. Moreover, even after completion of rehabilitation
relapse poses a major problem. Major predictors of post-
treatment relapse have been identified in large observa-
tional studies, including substance use patterns prior to
treatment, psychiatric comorbidities, social and psycho-
logical characteristics as well as craving [4–9].
We recently showed in a randomized controlled
study that heart rate variability (HRV) biofeedback in
addition to standard rehabilitation care for alcohol
dependence can reduce craving and anxiety more ef-
fectively than rehabilitative treatment alone [10]. In
this study, we also observed improvement in cardiac
autonomic and neurovascular function in patients
undergoing biofeedback possibly mediated by counter-
balancing a chronic shift toward an increased sympa-
thetic and decreased parasympathetic tone. However,
our short-term follow-up data did not answer the
question whether the observed improvements in psy-
chometric and cardiac autonomic endpoints translate
into reduced risk of post-treatment relapse.
In this follow-up study we aimed to determine the re-
lapse rate 1 year after HRV-biofeedback training and inte-
grative inpatient rehabilitative treatment in order to
explore potential treatment effects and acquire first long-
term data that could form a basis for confirmatory re-
search in large study populations. Furthermore, we sought
to identify predictors of abstinence following combined
rehabilitative and HRV-biofeedback treatment.
Methods
Study design and population
This is a one-year follow-up survey study after a ran-
domized controlled trial on the effects of HRV-
biofeedback on cardiac autonomic function assessed via
time and frequency domain parameters of HRV, auto-
nomic neurovascular function assessed via laser Doppler
flowmetry of cutaneous blood flow after sympathetic
stimulation as well as craving, anxiety and depressive
symptoms evaluated using psychometric tests. These
techniques were reported in detail elsewhere [10].
Briefly, male and female patients undergoing inpatient
rehabilitation treatment for alcohol use disorder received
either HRV-biofeedback in addition to standard rehabili-
tative care or standard rehabilitative care only. The study
intervention comprised application of a validated
HRV-biofeedback system (StressPilot™; BioSign, Otten-
hofen, Germany) with continuous measurement and
real-time visualization of HRV. Study subjects were
instructed to breathe at a given frequency of six cycles
per minute to increase the parasympathetic tone and
thereby HRV. Patients in the HRV-biofeedback group
underwent three 20-min sessions of HRV-biofeedback
training per week over 2 weeks whereas control pa-
tients did not undergo biofeedback. Psychometric test-
ing, and assessment of neurovascular and autonomic
cardiac function were undertaken before the beginning
of the first biofeedback session, immediately after
completion of the last biofeedback session as well as 3
and 6 weeks afterwards.
To perform a one-year follow-up assessment of abstin-
ence, study participants were contacted by mail 1 year
after discharge from rehabilitative therapy after having
given written permission to be contacted during in-
patient treatment. They were asked to answer a standard
questionnaire about their social situation, alcohol and
drugs consumption, as well as need for further institu-
tional treatment in the period of 12 months after dis-
charge. Abstinence from alcohol and drugs was
considered no consumption during 12 months after dis-
charge from our clinic. We extracted demographic char-
acteristics in subjects who had undergone HRV-
biofeedback in addition to rehabilitation 1 year earlier
and those who had received rehabilitative treatment
alone from the original dataset.
Comparison of abstinence rates
Abstinence rates 1 year after discharge from the rehabili-
tative therapy were evaluated applying standard criteria of
the German Society for Addiction Research and Addiction
Treatment [11]. Individuals who have not consumed any
alcohol since discharge from the inpatient treatment were
considered abstinent whereas any alcohol consumption
post-rehabilitation was defined relapse. In a first analysis
we included all patients who participated in the original
study protocol and returned our survey 1 year later to
compare rates of abstinence in patients that had been allo-
cated to the HRV-biofeedback group and those who had
undergone rehabilitative treatment alone during the RCT.
We then went on and repeated the comparative analysis
applying an intention-to-treat approach, including the en-
tire study population of the RCT irrespective of whether
they have participated in the one-year follow-up. In this
more conservative analysis, non-responders were consid-
ered to have relapsed.
Analysis of factors related to abstinence
In order to define individual factors related to abstinence
we compared patients who reported being abstinent 1
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year post-intervention and those who reported relapse in
terms of demographic characteristics as well as psycho-
metric measurements and parameters of the autonomic
cardiac function. These analyses were performed in pa-
tients who completed follow-up. We included in our
analyses psychometric scores at baseline and those ob-
tained immediately following the final HRV-biofeedback
training session (post-biofeedback or post-observation
period for patients in the control group). Psychometric
scores were obtained using the Obsessive Compulsive
Drinking Scale, as measure of craving as well as the sub-
scales Anxiety and Depression from the Symptom
Checklist-90, as measures of anxiety and depression.
Measures of the cardiac autonomic function comprised
the time-domain parameter coefficient of variation of R-
R intervals (CVNN) and frequency-domain parameters
high frequency (HF), low frequency (LF) and total power
(TP) at baseline and immediately post-biofeedback or
observation period. In order to improve our understand-
ing of the association between applied treatments, and
sustained abstinence, this analysis was undertaken in
both the biofeedback and the control group.
We then went on to identify specific predictors of ab-
stinence after rehabilitative inpatient care by relating
baseline data extracted from the original dataset of the
randomized controlled trial to data from the present sur-
vey. We conducted these analyses separately for control
patients and those who had received HRV-biofeedback.
In order to identify any specific changes in biological or
psychological characteristics due to HRV-biofeedback
which relate to sustained abstinence, analyses were re-
peated using data on patient characteristics and out-
comes obtained immediately after completion of the
biofeedback intervention, the duration of the control
period, respectively.
Statistical analysis
Statistical analyses were performed using SPSS ® 21
(IBM, Armonk, NY, USA). Dichotomous data were com-
pared using 2 test in patients who completed follow-
up. Continuous data on study population characteristics
were compared between patients who had received
HRV-biofeedback in addition to rehabilitation and those
who had undergone rehabilitative treatment only using
Student’s t–test or Mann-Whitney U test, according to
distribution. The same tests were used to compare study
population characteristics and post-biofeedback out-
comes between patients who reported abstinence after 1
year and those who had relapse. These analyses were
first undertaken in those patients that have participated
in the follow-up assessment excluding those that have
not returned the survey questionnaire. The same tests
were then applied to undertake an intention-to-treat
analysis in the entire study population, considering those
who have not participated in the one-year follow-up to
have relapsed. Comparisons between patients with and
without achievement of on-year abstinence were per-
formed separately for the biofeedback and the control
group. Alpha level for statistical significance was set to
0.05. Bivariate logistic regression analyses were under-
taken to identify possible predictor variables among
demographic and outcome variables with respect to one-
year abstinence in patients who completed follow-up.
Those variables that emerged as predictors of abstinence
were included in multivariate models with adjustment
for demographic characteristics. Unstandardized B-
coefficients (ß) and p-values were computed.
Results
Demographic characteristics
Among 48 study participants who have been contacted
by mail, 27 responded and completed the questionnaire
(56.2%; 15 biofeedback and 12 control patients, 18 males
and 9 females, ages 42.9 ± 8.6, mean ± SD). Demo-
graphic characteristics of patients who completed
follow-up are shown in Table 1. Within this population,
there were no differences in age, gender, tobacco use,
neuropathy and number of cases of liver disease between
patients who have undergone biofeedback in addition to
rehabilitative treatment and those who have undergone
rehabilitation only. (Table 1) Demographic characteris-
tics of the study population which consists of all patients
included in the intention-to-treat analysis are reported
elsewhere and have been additionally amended to Table
1 [10].
Abstinence
When including only patients who completed follow-up
in the analyses, abstinence rates tended to be higher in
those who had undergone HRV-biofeedback in addition
to rehabilitation compared to those who received re-
habilitative treatment alone. Similarly, the intention-to-
treat analysis, where patients who have not completed
follow-up were considered to have relapsed, also showed
a trend toward higher abstinence rates among patients
who had undergone HRV-biofeedback than those who
underwent rehabilitation alone (Fig. 1).
Characteristics of abstinent patients vs. relapse patients
In order to identify factors important to abstinence we
compared demographic characteristics as well as out-
come data on psychometric tests and autonomic cardiac
function at baseline and immediately after completion of
the RCT between patients who showed abstinence 1 year
after completion of the trial and those who had relapse.
As shown in Table 2, none of the included study popula-
tion characteristics were different between abstinent
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patients and those who had relapse. This was true for
both, the biofeedback group and the control group.
Logistic regression analyses
None of the assessed demographic and outcome vari-
ables were associated with abstinence 1 year after the
HRV-biofeedback intervention. (Table 3) The same was
true for control patients who underwent rehabilitation
care alone. As bivariate models did not reveal any sig-
nificant associations, no multivariate models were built.
Discussion
In this follow-up study 1 year after a randomized con-
trolled trial of HRV-biofeedback in patients with alcohol
addiction, we observed a tendency toward higher
rates of long-term abstinence in the interventional
study arm when compared with patients of the con-
trol arm that have not undergone HRV-biofeedback.
Viewed in conjunction with our previous observation
of improvement in cardiac autonomic and neurovas-
cular function and reduction of craving and anxiety
after HRV-biofeedback in the same study population,
these findings warrant follow-up research to confirm
this trend in a larger study population and assess
the neurophysiological mechanisms whereby HRV-
biofeedback might alter long-term abstinence [10].
Although our study was not powered to show sig-
nificant group differences 1 year post-treatment, our
data might contribute to generating the hypothesis
that HRV-biofeedback has beneficial effects on long-
term abstinence.
A recent randomized clinical trial had confirmed that
HRV-biofeedback as adjuvant therapy leads to reduced
craving in patients with addiction to alcohol and drugs
[12]. Similar to our previous randomized controlled trial,
this investigation has been able to show a trend toward
improvement of autonomic cardiac function following
the intervention. While long-term abstinence has not
been assessed in this study, the observed weak short-
term effect on HRV might offer an explanation why in
our study changes in abstinence 1 year post-intervention
did not reach statistical significance. In both studies, the
duration and frequency of HRV-biofeedback training
was limited, corresponding to 6 treatment sessions over
a period of 2 weeks in our RCT and 3 sessions during
3 weeks in the work of Eddie et al. This relatively short
treatment regimen might have been insufficient to
achieve an improvement in autonomic cardiac function
which influences craving, and thereby chance of relapse,
to a degree which translates into long-term abstinence
beyond the duration of the intervention. Although our
RCT showed that at follow up 3 weeks post-
intervention, HRV was already decreasing toward
Table 1 Demographic Characteristics
Patients who completed follow-up Intention-to-treat
HRV Biofeedback
(n = 15)
Control
(n = 12)
p-value HRV Biofeedback
(n = 24)
Control
(n = 24)
p-value
Age (years) 41.2 ± 8 43.6 ± 9 0.74 40 ± 7 44 ± 8 0.06
Gender (%) 53.3 m, 46.7 f 83.3 m, 16.7 f 0.09 70.8 m, 29.2 f 70.8 m, 29.2 f 0.09
Smoking (%) 80 75 0.75 79 75 0.36
Comorbidities
• Neuropathy (%) 26.7 0 0.05 33.3 16.7 0.09
• Hepatic steatosis (%) 20 50 0.05 20.8 37.5 0.07
Analyses of demographic data showed no differences in size, weight, gender, tobacco use and comorbidities between patients who have undergone HRV-biofeedback
one year earlier and those who have received rehabilitation only. This was true when both, only patients who completed follow-up or all participants of the
interventional randomized controlled trial (Intention-to-treat) were included in the analyses
m male, f female
Fig. 1 Abstinence rate one year after discharge from the
rehabilitative therapy. The bar graph shows the rates of one-year
abstinence in each study arm (HRV-biofeedback and control). Results
are separately displayed for patients who completed follow-up and
the entire population (intention-to-treat). A non-significant trend
toward increased abstinence one year post-HRV-biofeedback (red
bars) compared with control patients who have not undergone the
intervention (blue bars) was observed when only complete cases
were included. This was also true in the intention-to-treat analysis
where patients who have not completed follow-up were considered
to have relapsed was performed
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baseline, the reduction in craving was sustained until the
last follow up 6 weeks post-intervention. In fact, treat-
ment with HRV-biofeedback can improve psychometric
measures such as subjective fatigue independent from
changes in autonomic cardiac function [13]. Taken to-
gether, this might implicate that HRV-biofeedback treat-
ment has to be applied more often and over a longer
time period to achieve a sustained effect on craving and
thereby abstinence. However, dose-response studies in
larger study populations seem necessary to elucidate the
therapeutic potential of this treatment to improve out-
comes of rehabilitation for alcohol addiction.
Moreover, the underlying mechanism whereby im-
provement of the autonomic cardiac function leads to al-
leviation of craving, and possibly changes in abstinence,
needs to be elucidated. The observed effect of HRV-
biofeedback on autonomic cardiac function and craving
might be explained by the physiological mechanism of
action of this technique. HRV-biofeedback is a behav-
ioral intervention that targets enhancement of the beat-
to-beat fluctuations of the heart rate (HRV) due paced
breathing. Physiologically, the heart rate is determined
by the intrinsic sinoatrial node discharge rate as well its
autonomic alteration mediated by cardiac sympathetic
and parasympathetic activity [14]. The preganglionic
sympathetic and parasympathetic outflow is determined
by the central autonomic network (CAN), a functional
unit of the central nerve system which regulates adaptive
visceromotor and behavioral responses to internal and
environmental stimuli [15]. Interestingly, there is an
overlap between the CAN and the anterior executive re-
gion (AER), another functional network of brain centers
which is responsible of assessing the motivational con-
tent of internal and external stimuli and regulating
context-dependent behaviors. Cerebral centers that are
part of both CAN and AER comprise the insular, anter-
ior cingulate and prefrontal cortices as well as the amyg-
dala and the periaquaductal gray [16]. The functional
overlap of these centers viewed in conjunction with the
previous observation of reduced HRV in several mental
disorders support the concept of HRV constituting an
index of individual self-regulation and psychological
flexibility [17, 18]. Although the exact neurophysio-
logical interaction between CAN and AER is poorly
Table 2 Characteristics comparison between abstinent and relapsed patients from HRV-biofeedback and control groups
HRV-biofeedback p-value Control p-value
Abstinent
(n=10)
Relapse
(n=5)
Abstinent
(n=6)
Relapse
(n=6)
Demographic factors
Age (years) 44.0±6.0 39.8±9,3 0.37 44.0±5.3 43.3±12.7 0.9
Gender (%) 80 m, 20 f 40 m, 60 f 0.13 83.3 m, 16.7 f 83.3 m, 16.7 f 1.0
Smoking (%) 80 80 1.0 83.3 66.7 0.5
Psychometric characteristics
Craving at baseline 15.2±13.1 11.9±11.3 0.62 10.0±5.4 10.2±1.8 0.94
Craving post-intervention 10.0±10.0 8.8±8.8 0.85 6.5±4.9 5.5±5.4 1.0
Anxiety at baseline 6.0±3.8 6.2±5.2 0.94 5.8±5.2 3.2±3.2 0.31
Anxiety post-intervention 4.0±3.7 5.1±7.3 1.0 3.8±2.9 3.2±3.9 0.58
Depression at baseline 9.4±7.3 11.3±9.0 0.69 9.5±7.2 8.2±5.8 0.73
Depression post-intervention 5.4±5.1 10.5±10.8 0.37 6.7±5.5 6.5±6.3 0.81
Heart rate variability
CVNN at baseline (%) 3.5±1.1 5.1±2.1 0.15 3.6±0.7 4.9±1.6 0.11
CVNN post-intervention (%) 4.5±1.21 5.5±1.7 0.27 3.5±1.3 5.4±2.7 0.16
HF at baseline (ms2) 222.8±258.8 606.6±1331.2 0.2 193.1±182.5 310.4±312.3 0.81
HF post-intervention (ms2) 93.4±101.5 405.9±400.9 0.07 86.2±42.3 1074.8±1589.1 0.31
LF at baseline (ms2) 229.9±122.7 681.96±811.4 0.16 260.6±216.0 674.9±665.8 0.18
LF post-intervention (ms2) 546.5±409.5 615.82±573.9 0.85 343.9±317.2 1246.2±2444.4 0.81
TP at baseline (ms2) 915.8±659.7 2332.2±2475.8 0.16 1255.3±1331.8 1425.4±1248.9 1.0
TP post-intervention (ms2) 1138.3±597.7 1945.7±1773.6 0.44 713.9±539.3 2480.8±4048.6 0.39
Analyses revealed no differences between abstinent patients and those who had relapse in any of the included demographic, psychometric or HRV parameters.
Among patients who completed follow-up, this was true both in between patients who have undergone HRV-biofeedback one year earlier and those who have
received rehabilitation only. “Craving” refers to the Obsessive Compulsive Drinking Scale score. “Anxiety” and “Depression” refer to scores of subscales Anxiety and
Depression from the Symptom Checklist-90
CVNN coefficient of variation of R-R intervals, HF high frequency, LF low frequency, TP total power
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elucidated, their common capacity of altering HRV might
explain why improvement of HRV could also lead to
stabilization of craving and anxiety in alcohol dependent
patients. Interestingly, decrease in high frequency HRV, a
spectral analysis based parameter of parasympathetic ac-
tivity, has been shown to predict alcohol craving inde-
pendent of age, anxiety and levels of alcohol consumption.
This suggests that impaired cardiac parasympathetic func-
tion is associated with increased measures of craving [19].
Furthermore, HRV reactivity to cue-exposure has been
pointed as a predictor of relapse after treatment independ-
ent of therapeutic regime and after controlling for the se-
verity of the alcohol dependence [20]. In fact,
neuroimaging studies showed that patients with alcohol
use disorder exposed to alcohol-related cues which induce
craving, i.e. alcohol print advertisements or images (or the
taste or smell) of their favorite alcoholic beverage, present
activation of ventral striatum, anterior cingulate and
ventromedial prefrontal cortices [21].
Our study is limited by a low return rate of the
mailed questionnaires. Therefore, the observed differ-
ences in abstinence rates between HRV-biofeedback
treated and control patients might not have reached
statistical significance due to a type two error. In the
intent-to-treat analysis, statistical power might have
been compromised by the conservative approach of
imputing missing data, where all patients who have
not completed follow-up were considered to have re-
lapsed. This limitation might be overcome by in-
creasing the sample size in future studies.
Alternatively, it might be necessary to increase the
frequency and duration of the HRV-biofeedback
treatment sessions to translate the observed trend
into a significant long-term difference.
We did not assess the amount of past-year drink-
ing, therefore we cannot comment on possible asso-
ciations between treatment with HRV-biofeedback
and the severity of relapse. Furthermore, patients
weren’t asked to continue paced breathing after the
intervention and therefore we haven’t assessed the
rate of those still practicing the breathing technique
after discharge. This might further explain why in
our study observed trends of increase in abstinence
have not reached statistical significance.
Table 3 Bivariate linear regression analyses
HRV-biofeedback
(n=15)
Control
(n=12)
Unstandardized
B coefficient
p- value Unstandardized
B coefficient
p-value
Demographic factors
Age 0.07 0.35 <0.01 0.89
Gender 1.79 0.16 0.00 1.00
Smoking 0.67 0.32 0.20 0.78
Psychometric characteristics
Craving at baseline 0.02 0.59 -0.01 0.93
Craving post-intervention 0.01 0.79 0.04 0.71
Anxiety at baseline -0.10 0.93 0.16 0.29
Anxiety post-intervention -0.03 0.73 0.06 0.79
Depression at baseline -0.03 0.66 0.03 0.70
Depression post-intervention -0.08 0.33 >0.01 0.95
Heart rate variability
CVNN at baseline -0.65 0.17 -1.07 0.16
CVNN post-intervention -0.54 0.26 -0,79 0.21
HF at baseline <-0.01 0.26 <-0.01 0.41
HF post-intervention <-0.01 0.26 <-0.01 0.30
LF at baseline <-0.01 0.23 <-0.01 0.22
LF post-intervention 0.00 0.79 <-0.01 0.48
TP at baseline 0 0.46 <0.01 0.75
TP post-intervention <0.01 0.79 <-0.01 0.32
Regression analyses in patients who completed follow-up did not reveal any predictors of abstinence among demographic, psychometric or HRV parameters both
in patients who have been treated with HRV-biofeedback and controls. “Craving” refers to the Obsessive Compulsive Drinking Scale score. “Anxiety” and “Depression”
refer to scores of subscales Anxiety and Depression from the Symptom Checklist-90
CVNN coefficient of variation of R-R intervals, HF high frequency, LF low frequency, TP total power
Penzlin et al. BMC Psychiatry  (2017) 17:325 Page 6 of 8
Taken together, our study forms a basis for a long-
term investigation of HRV-biofeedback in patients with
alcohol addiction which should include a larger sample
size and a dose-response protocol to identify the optimal
regimen and achieve a sustained improvement in craving
and autonomic function. This, in turn, might translate
into improved long-term abstinence.
Conclusions
Our data suggest that HRV-biofeedback might contrib-
ute to long-term abstinence when applied in addition to
rehabilitation care. Since the trends observed in this
follow-up study did not reach statistical significance, fur-
ther research is warranted to confirm this hypothesis in
a larger study population.
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